My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: not usually. Compounded GLP‑1s are an option of last resort because they aren’t FDA‑approved, may be inconsistent in dose/purity, and are generally not covered by insurance. In most cases there are safer, better‑supported alternatives to try first.

What I recommend you do next

1. Confirm the reason for denial. Call your insurer and get the specific denial code and appeal instructions (prior authorization denied? not medically necessary? step therapy?).
2. Ask your prescriber to appeal. A written letter of medical necessity and a peer‑to‑peer review request from your doctor often overturn denials — include BMI, weight‑related conditions (hypertension, sleep apnea, diabetes), and prior weight‑loss attempts.
3. Check manufacturer help first:
   • Novo Nordisk (Wegovy/Ozempic/Rybelsus) — they offer savings programs and patient assistance resources for eligible patients. Ask your clinician or call Novo Nordisk patient support.
   • Eli Lilly (Mounjaro for diabetes; Zepbound is their weight‑loss tirzepatide) — Lilly has patient assistance and savings resources as well. Manufacturer programs often cut out‑of‑pocket cost or provide free samples while appeals are pending.
4. Ask about alternative FDA‑approved GLP‑1s your plan might cover:
   • Ozempic (semaglutide injection, approved for diabetes) or Rybelsus (oral semaglutide) — sometimes covered more easily than Wegovy.
   • Mounjaro (tirzepatide, for diabetes) or Zepbound (tirzepatide for weight management) — some insurers cover these and they can be more effective for weight loss in many patients. Your prescriber can check coverage for these and request exceptions.
5. Use discount tools while you sort coverage: GoodRx, SingleCare, or manufacturer copay cards sometimes help with out‑of‑pocket cost for branded drugs.
6. Consider other routes: clinical trials, structured medical weight‑management programs, or bariatric referral if you qualify.

About compounded GLP‑1s

• Risks: not FDA‑approved; potency, sterility, and impurities can vary. The FDA has warned about compounding GLP‑1s from bulk drug substances. Adverse events might be harder to trace.
• Coverage and cost: insurers typically won’t pay for compounded versions, so you may still pay full price.
• If you’re considering a compound: only use a reputable, accredited compounding pharmacy (PCAB accreditation if available), ask for a certificate of analysis, sterility testing results, and clear instructions. Discuss risks with your clinician and get it in writing.

If you want, I can:

• Help draft a sample appeal/letter of medical necessity your clinician can adapt.
• Check likely coverage differences among Wegovy/Ozempic/Rybelsus/Mounjaro/Zepbound (tell me your insurer if you want specific tips).
• Find nearby PCAB‑accredited compounders if you still want that route.